Boston Scientific Corp. (NYSE: BSX) has a price-to-earnings ratio that is above its average at 71.25x. The stock has a 36-month beta value of 0.80. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 10 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BSX is 1.47B, and at present, short sellers hold a 0.74% of that float. On October 21, 2024, the average trading volume of BSX was 5.56M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BSX) stock’s latest price update
The stock of Boston Scientific Corp. (NYSE: BSX) has increased by 1.91 when compared to last closing price of 86.42.Despite this, the company has seen a gain of 1.11% in its stock price over the last five trading days. prnewswire.com reported 2024-10-18 that New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE™ Pulsed Field Ablation (PFA) System.
BSX’s Market Performance
Boston Scientific Corp. (BSX) has seen a 1.11% rise in stock performance for the week, with a 5.21% gain in the past month and a 12.52% surge in the past quarter. The volatility ratio for the week is 1.78%, and the volatility levels for the past 30 days are at 1.51% for BSX. The simple moving average for the last 20 days is 3.35% for BSX’s stock, with a simple moving average of 20.10% for the last 200 days.
Analysts’ Opinion of BSX
Goldman, on the other hand, stated in their research note that they expect to see BSX reach a price target of $90. The rating they have provided for BSX stocks is “Buy” according to the report published on May 30th, 2024.
Mizuho gave a rating of “Buy” to BSX, setting the target price at $80 in the report published on February 01st of the current year.
BSX Trading at 6.92% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.02% of loss for the given period.
Volatility was left at 1.51%, however, over the last 30 days, the volatility rate increased by 1.78%, as shares surge +4.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.57% upper at present.
During the last 5 trading sessions, BSX rose by +1.11%, which changed the moving average for the period of 200-days by +52.90% in comparison to the 20-day moving average, which settled at $85.21. In addition, Boston Scientific Corp. saw 52.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Mahoney Michael F, who sale 162,777 shares at the price of $84.63 back on Oct 07 ’24. After this action, Mahoney Michael F now owns 1,572,096 shares of Boston Scientific Corp., valued at $13,775,792 using the latest closing price.
Fitzgerald Joseph Michael, the EVP & Group Pres, Cardiology of Boston Scientific Corp., sale 132,527 shares at $85.00 during a trade that took place back on Oct 07 ’24, which means that Fitzgerald Joseph Michael is holding 160,467 shares at $11,264,888 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.67 for the gross margin
The net margin for Boston Scientific Corp. stands at 0.12. The total capital return value is set at 0.09. Equity return is now at value 9.46, with 5.16 for asset returns.
Based on Boston Scientific Corp. (BSX), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is 9.81.
Currently, EBITDA for the company is 3.62 billion with net debt to EBITDA at 2.05. When we switch over and look at the enterprise to sales, we see a ratio of 9.04. The receivables turnover for the company is 6.34for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
To sum up, Boston Scientific Corp. (BSX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
